Business Context and Reporting Period
This Form 8-K filing by Zimmer Biomet Holdings, Inc. (the "Company") reports on events occurring on December 18 and 19, 2017. The primary purpose of the filing is to disclose the appointment of Bryan C. Hanson as President and Chief Executive Officer (CEO) and his election to the Board of Directors, effective December 19, 2017. Mr. Hanson succeeds Daniel P. Florin, who served as Interim CEO from July 11, 2017, through December 19, 2017. Mr. Florin will continue to serve as Senior Vice President and Chief Financial Officer.
Key Financial Metrics
This filing does not contain operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The financial data presented relates exclusively to the compensation and severance arrangements for the new CEO.
- Base Salary: $1,050,000 annually.
- Target Annual Bonus: 130% of base salary.
- One-Time Sign-On Equity (Fair Value): Approximately $7,100,000 total ($3,550,000 in NQSOs and $3,550,000 in PRSUs).
- One-Time Replacement Equity (Fair Value): Approximately $8,589,000 total ($2,750,000 NQSOs, $3,089,000 RSUs, $2,750,000 PRSUs).
- 2018 Annual Equity Grant (Fair Value): Approximately $7,100,000.
- One-Time Cash Bonus: $573,000 (subject to forfeiture documentation and repayment if voluntarily terminated within one year).
- Interim CEO Salary Adjustment: Mr. Florin's salary reverts to $583,500 annually effective December 19, 2017.
Material Changes Versus Prior Period
The material change reported is the transition of executive leadership. Bryan C. Hanson, formerly Executive Vice President and President of the Minimally Invasive Therapies Group at Medtronic, has replaced Daniel P. Florin as the permanent CEO. This concludes the interim leadership period that began in July 2017. Additionally, the Company has established a new compensation structure for the CEO role, including significant equity incentives and severance protections not previously detailed for this specific tenure.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing does not provide financial guidance or operational outlook. It focuses on the strategic appointment of Mr. Hanson to lead the Company.
Compensation Risks and Contingencies:
- Equity Cancellation: The one-time sign-on equity awards are subject to cancellation unless Mr. Hanson executes an open market purchase of at least $3,000,000 of Company common stock within the first 90 business days of employment.
- Severance Triggers: Significant severance payments are contingent upon specific termination events. Involuntary termination without cause entitles Mr. Hanson to two times the sum of base salary and target bonus plus 24 months of COBRA. Termination following a change in control (without cause or for good reason) entitles him to three times the sum of base salary and target bonus, full vesting of equity, and other benefits.
- Golden Parachute Tax: The Change in Control Severance Agreement includes a "cutback" provision to reduce payments if they would trigger the excise tax under Section 4999 of the Internal Revenue Code.
- Restrictive Covenants: Mr. Hanson is subject to a two-year non-compete, non-solicitation, and confidentiality agreement post-employment.
Important Facts for Investor Verification
- Verify the execution of the required $3,000,000 open market stock purchase by Mr. Hanson within 90 days to ensure the sign-on equity awards are not cancelled.
- Review the specific performance goals attached to the Performance-Based Restricted Stock Units (PRSUs) to understand the conditions for vesting.
- Monitor the transition of leadership responsibilities from Mr. Florin to Mr. Hanson and any subsequent strategic shifts announced by the new CEO.
- Note that the filing explicitly states the press release and related information are "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the information contained therein.